SQ-LIP-000002 · v1.6 (archived) · View current version →
How common is lipedema, and who does it affect?
Also asked as
- What is the prevalence of lipedema and which populations are most affected?
- How many people get lipedema, and who is most likely to have it?
- lipedema prevalence and affected demographics
- Who tends to develop lipedema, and how often does it occur?
Lipedema affects almost exclusively women, usually starting around hormonal life stages like puberty or pregnancy, and is frequently undiagnosed; commonly cited estimates suggest it may affect roughly 1 in 9 adult women. How common it truly is remains uncertain, because the figures come from clinic-based, self-report, or review sources rather than a high-quality general-population study.
- Current answer
- Lipedema presents almost exclusively in women across every clinical cohort reviewed (U.S., German, Swiss, Italian, Brazilian, Swedish, and Saudi samples) and in multiple reviews.
- Knowledge state
- Emerging · Evidence confidence: very low–low (GRADE) · Stability: Evolving
- Evidence
- 6 consistent · 0 conflicting · 13 refining / contextual
- ⚠ none indexed yet — the registry may under-detect disconfirming evidence (a known limitation)
- Evidence verification
- 26/26 sources independently verified
- Main limitation
- No high-quality population-based prevalence/incidence study exists; the widely repeated ~11% (1 in 9 women) figure traces to clinic samples, self-report screening, and reviews, so…
- Latest change
- This update added a moderate-quality surgical cohort (191 women) and a narrative review that reinforce female predominance, hormonal-onset timing, frequent… · v1.6
- Knowledge freshness
- 69% recent · mixed
- Last updated
- 2026-06-07 · v1.6
Based on currently indexed evidence, lipedema presents almost exclusively in women across every clinical cohort reviewed (U.S., German, Swiss, Italian, Brazilian, Swedish, and Saudi samples) and in multiple reviews. Male occurrence is rare but documented (a case series of 5 men with the classical phenotype, isolated case reports, and consensus that 'occurrence in men is rare'); obesity is described as a principal aggravating factor in both sexes. Symptom onset is most commonly linked to periods of hormonal change — puberty (reported in ~48–62% of patients across cohorts; median onset age ~14.8 years in one prospective cohort), pregnancy (~22–41%), and less often menopause; an autosomal-dominant inheritance pattern with female preference has been proposed. True population prevalence remains poorly defined. The most consistent figures come from clinical/lymphology settings and reviews: a systematic review compiled estimates of ~11% in women (Földi), ~15% in a lymphology clinic (Herpertz), and 18.8% of 843 patients with lower-limb enlargement, with lymphology-clinic prevalence reported at 6.5–18.8%; multiple narrative reviews and clinical cohorts repeat an approximate figure of 1 in 9 adult women (~11%), and 15–17% of patients treated for lymphedema reportedly have concomitant lipedema. A Saudi cross-sectional study (low quality) clinically confirmed lipedema in 71% of 115 patients with lower-limb edema. A Brazilian screening-based study estimated probable lipedema at ~12.3% of adult women, but this relies on a self-reported validated questionnaire without clinical confirmation, carries a low evidence grade, and was endorsed with the lowest agreement in a 2025 consensus — likely an overestimate of clinically diagnosed disease. These prevalence estimates derive largely from low-grade reviews, case reports, and clinic-based (selection-biased) samples, so population incidence and true prevalence remain undetermined; the recurring ~11% figure is widely cited but not anchored in a high-quality population survey. Clinical cohort data (including moderate-quality U.S., Swiss, and prospective cohorts) describe a condition spanning middle adulthood (mean ages ~38–49 years), with first manifestation typically in adolescence (a Swedish survey reported 69% with onset before age 30) and prolonged diagnostic delay — mean ~15 years in one German cohort and a median exceeding 25 years in a prospective cohort; the Swedish survey found peak age at diagnosis only at 50–59 years. Underrecognition is striking: 77% of confirmed Saudi patients were previously undiagnosed, a cited UK study found 93% of patients with lipedema signs/symptoms were unrecognized by their physicians, and additional reviews/surgical cohorts describe the condition as commonly misdiagnosed. Family history is reported by roughly 16–85% of patients across sources (~46–50% in larger cohorts, up to 85% in one prospective cohort), suggesting a heritable component of undetermined genetic background. Lower-limb (Type III, ankle-to-hip) involvement predominates (~71%) in multiple cohorts. Lipedema is not exclusive to overweight/obese women (documented persisting in a woman with BMI 15 kg/m²), and it carries substantial comorbidity burden including hypothyroidism, depression, anxiety, migraine, chronic venous disease, hypertension, anemia, vitamin D insufficiency, autoimmune thyroiditis, polycystic ovary syndrome, and reduced quality of life across multiple independent cohorts. A BMI-stratified study further shows that within lipedema populations, clinical and subclinical lymphedema rise sharply with increasing BMI (a dose-response gradient).
A synthesis rendered from the currently indexed evidence — versioned, not a verdict.
⚙ AI consolidation: Claude Opus 4.8 · 2026-06-07 — evidence-bounded; the AI does not opine
This update added a moderate-quality surgical cohort (191 women) and a narrative review that reinforce female predominance, hormonal-onset timing, frequent misdiagnosis, and the ~11% prevalence figure, without providing new population-level estimates.
Knowledge freshness = share of the 26 indexed evidence sources from the last 5 years (newest 2026, oldest 2012) . Low freshness flags an ageing evidence base — not that the answer is wrong.
Evidence over time
consistent conflicting refining / contextual Each dot is a study, placed by year and coloured by whether the linked claim supports or contradicts the answer. As the surveillance loop runs, claim revisions and new evidence will extend this timeline. The hollow ring marks the first time this topic appears in the literature.
Answer over time
Each node is a published version of the answer — open one to read the answer exactly as it stood then.
Choose a format (Vancouver default). Citing a version captures the evidence state on that date; this page shows the current version — see version history.
Consistent claims
- SCR-LIP-000012 consistent
The estimated prevalence of probable lipedema among adult Brazilian women is approximately 12.3%, indicating a common rather than rare condition.
Prevalência e fatores de risco para lipedema no Brasil — Amato et al. (2022) · Brazilian Consensus Statement on Lipedema using the Delphi methodology — Amato et al. (2025) · Lipedema prevalence and risk factors in Brazil — Amato et al. (2022) - SCR-LIP-000138 consistent
This systematic review reports lipedema prevalence estimates of 11% in women (Földi), 15% of patients in a lymphology clinic (Herpertz), and 18.8% of 843 patients with lower-limb enlargement, occurring almost exclusively in women, with positive family history in 16–64% of cases.
Lipedema: an overview of its clinical manifestations, diagnosis and treatment of the disproportional fatty deposition syndrome – systematic review — Forner‐Cordero et al. (2012) - SCR-LIP-000141 consistent
In a Saudi cross-sectional study of 115 patients with lower-limb edema, lipedema was clinically confirmed in 71%, affected only women with mean age 38.6 years and mean BMI 30.5, with disease onset typically at ages 20-39, perceived triggers being puberty (49%), pregnancy (22%), and massive weight loss (22%), a positive family history in 46% (predominantly mothers and sisters), and 77% being previously undiagnosed.
Characteristics and Clinical Features of Patients with Lipedema in Saudi Arabia: A Cross-sectional Comprehensive Assessment — Alosaimi et al. (2024) - SCR-LIP-000142 consistent
Lipedema is a chronic disorder presenting almost exclusively in women, typically beginning during periods of hormonal change such as puberty, childbirth, or menopause, with familial aggregation suggesting an autosomal dominant inheritance pattern and an estimated prevalence of 11–15% of adult women.
Lipedema: friend and foe — Torre et al. (2018) · Lipedema and obesity: A narrative review and treatment protocol. — Rathod S, Pouwels S, Schmidt J. (2026) - SCR-LIP-000266 consistent
This review estimates lipedema affects approximately 1 in 9 adult women, occurs almost exclusively in women with bilateral symmetric limb adiposity sparing the feet, and notes 15-17% of patients treated for lymphedema have concomitant lipedema.
Lipedema: A Relatively Common Disease with Extremely Common Misconceptions — Buck & Herbst (2016) - SCR-LIP-000268 consistent
In a prospective cohort of 138 lipedema patients (median age 47.6 years), 85% reported a positive family history, 57% had symptom onset related to puberty (median onset age 14.8 years), and Type III (ankle-to-hip) involvement predominated at ~71%, with a median diagnostic delay exceeding 25 years.
PREVALENCE OF CLINICAL MANIFESTATIONS AND ORTHOPEDIC ALTERATIONS IN PATIENTS WITH LIPEDEMA: A PROSPECTIVE COHORT STUDY — Forner-Cordero et al. (2021)
Conflicting claims
- None indexed yet.
Refining / contextual
- SCR-LIP-000014 context
Lipedema occurs in men with the classical phenotype (bilateral, symmetrical, foot-sparing lower-limb fat accumulation, negative Stemmer sign), although it almost exclusively affects women and male occurrence is rare.
Lipedema in Men: A Retrospective Case Series of Five Patients From a Brazilian Referral Center — Amato et al. (2025) · Brazilian Consensus Statement on Lipedema using the Delphi methodology — Amato et al. (2025) - SCR-LIP-000076 context
In a national survey of 707 U.S. women with lipedema, the mean age was 48.6 years and mean BMI was 40.9 kg/m², with symptom onset most commonly at puberty (48.0%) or pregnancy (41.2%), and the condition exclusively affected women in this sample.
National survey of patient symptoms and therapies among 707 women with a lipedema phenotype in the United States — Aday et al. (2024) - SCR-LIP-000077 context
In a survey of 209 German female lipedema patients who underwent liposuction, the average age was 38.5 years, first manifestation occurred at age 16, and diagnosis took a mean of 15 years to achieve, with comorbidities including hypothyroidism (35.9%) and depression (23.0%) at rates exceeding general population prevalence.
New Insights on Lipedema: The Enigmatic Disease of the Peripheral Fat — Bauer et al. (2019) - SCR-LIP-000078 context
Lipedema is a serious disease with undetermined genetic background that affects women, first described as a syndrome in 1940, and is neither a cosmetic problem nor a lifestyle issue, though its true prevalence and incidence remain poorly defined in the literature.
Lipedema Research—Quo Vadis? — Ernst et al. (2022) - SCR-LIP-000079 context
In a retrospective series of 106 lipedema patients who underwent liposuction, the cohort was exclusively female with a median BMI of 31.6 kg/m², and showed elevated prevalence of obesity, hypothyroidism, migraine, and depression compared to non-lipedema populations, while diabetes (5%) and dyslipidemia (7%) prevalence were unexpectedly low.
Disease progression and comorbidities in lipedema patients: A 10‐year retrospective analysis — Ghods et al. (2020) - SCR-LIP-000080 context
In a Swiss referral centre cohort of 381 women with lipedema (mean age 41.9 years), 49.9% reported a family history, 62.2% reported symptom onset during adolescence, and 92.1% had comorbidities, with pain affecting 87.9% and significantly reduced quality of life in the majority.
Clinical characteristics, comorbidities, and correlation with advanced lipedema stages: A retrospective study from a Swiss referral centre — Luta et al. (2025) - SCR-LIP-000081 context
In a cohort of 360 Italian women with lipedema of the lower limbs (stages 1–3), the condition was found exclusively in women and was associated with comorbidities including vitamin D insufficiency, chronic venous disease, and dyslipidemia.
Observational Study on a Large Italian Population with Lipedema: Biochemical and Hormonal Profile, Anatomical and Clinical Evaluation, Self-Reported History — Patton et al. (2024) - SCR-LIP-000139 context
This case report of a 53-year-old male with lipedema notes that lipedema is less frequent in men than in women, that obesity is the principal aggravating factor in both sexes, and that the authors' case series detects lymphedema by multi-segment bioimpedance in 50% of individuals with lipedema and BMI above 30 kg/m2.
Lipedema in Male Progressing to Subclinical and Clinical Systemic Lymphedema — Pereira de Godoy et al. (2022) - SCR-LIP-000140 context
This case report cites epidemiological data estimating lipedema prevalence at approximately 11% of the female population, predominantly affecting women, and reports a UK study finding 93% of patients with lipedema signs/symptoms were unrecognized by their physicians; it also describes lipedema persisting in a woman with low BMI (15 kg/m²), demonstrating it is not exclusive to overweight/obese women.
A Young Woman with Excessive Fat in Lower Extremities Develops Disordered Eating and Is Subsequently Diagnosed with Anorexia Nervosa, Lipedema, and Hypermobile Ehlers-Danlos Syndrome — Wright & Herbst (2021) - SCR-LIP-000143 context
This systematic review of lipedema pathology notes that lipedema is a symmetrically localized, painful hypertrophy of subcutaneous adipose tissue in the extremities that almost exclusively affects females.
Auf der Suche nach der Evidenz: Eine systematische Übersichtsarbeit zur Pathologie des Lipödems — Funke et al. (2023) - SCR-LIP-000263 context
In 258 women with clinically diagnosed lipedema, the prevalence of subclinical systemic lymphedema and clinical lower-limb lymphedema increased progressively with BMI (Group I <30: 16.3% subclinical, 6.1% clinical; Group II 30-40: 48.3% and 51.6%; Group III 40-50: 72.2% and 77.8%; p=0.0001), and lipedema patients could develop edema even at normal weight.
Lipedema and the Evolution to Lymphedema With the Progression of Obesity — Pereira de Godoy et al. (2020) - SCR-LIP-000267 context
In a Swedish national survey of women with lipedema, 69% reported symptom onset before age 30 but the most frequent age at diagnosis was 50-59 years (34.9%), with the most common subtype being combined type 3+4 (buttocks-ankles plus arms) in 58.7% of participants.
Women with lipoedema: a national survey on their health, health-related quality of life, and sense of coherence — Falck et al. (2022) - SCR-LIP-000063 context
Lipedema is often misdiagnosed and affects approximately 11% (about 1 in 9) of adult women.
Observational Study of Ultrasound-Assisted Liposuction for Lower Limb Lipedema on 191 Female Patients — Hersant et al. (2026) · Lipedema: A Relatively Common Disease with Extremely Common Misconceptions — Buck & Herbst (2016) · Lipedema: A Call to Action! — Buso et al. (2019) · Lipedema: Progress, Challenges, and the Road Ahead — Cifarelli (2025)
Major uncertainty
No high-quality population-based prevalence/incidence study exists; the widely repeated ~11% (1 in 9 women) figure traces to clinic samples, self-report screening, and reviews, so the true general-population prevalence and the genetic basis of its female predominance remain undetermined.
Version history
- SQ-LIP-000002 · v1.6 — 2026-06-07 — This update added a moderate-quality surgical cohort (191 women) and a narrative review that reinforce female predominance, hormonal-onset timing, frequent misdiagnosis, and the ~11% prevalence figure, without providing new population-level estimates. · view this version
- SQ-LIP-000002 · v1.5 — 2026-06-02 — Answer recompiled after human curation of the claim set. · view this version
- SQ-LIP-000002 · v1.4 — 2026-05-31 — This update added a Swedish national survey (peak diagnosis at 50–59 despite onset <30 in 69%, combined type 3+4 most common) and a prospective cohort (85% positive family history, ~71% Type III involvement, median diagnostic delay >25 years), and reinforced the ~1-in-9 (~11%) prevalence estimate and the Brazilian ~12.3% figure (extrapolated to ~8.8 million women) with added comorbidity detail. · view this version
- SQ-LIP-000002 · v1.3 — 2026-05-31 — Answer recompiled after human curation of the claim set. · view this version
- SQ-LIP-000002 · v1.2 — 2026-05-31 — This update added multiple reviews and cross-sectional studies (notably a systematic review and a moderate-grade Saudi cohort) providing additional, convergent prevalence estimates (~11% in women, 6.5–18.8% in lymphology clinics, 71% clinically confirmed), reinforcing the BMI-dependent lymphedema gradient, and documenting profound underrecognition (77–93% undiagnosed) plus persistence at low BMI. · view this version
- SQ-LIP-000002 · v1.1 — 2026-05-31 — This update substantially expanded the epidemiological and demographic profile of lipedema by adding seven new context claims from large clinical cohorts (U.S., German, Swiss, Italian) and a scoping review, providing consistent data on age of onset, diagnostic delay, family history, reproductive milestone triggers, comorbidity burden, and quality of life impairment — none of which were present in the prior answer. · view this version
- SQ-LIP-000002 · v1.0 — 2026-05-30 — founding index (19 claims) · view this version
Key references
DOI:10.1590/1677-5449.202101981 · DOI:10.1590/1677-5449.202301832 · DOI:10.1590/1677-5449.202101982 · DOI:10.7759/cureus.87332 · DOI:10.1177/1358863x231202769 · DOI:10.1097/prs.0000000000006280 · DOI:10.3390/jpm13010098 · DOI:10.1111/dth.14534 · DOI:10.1371/journal.pone.0319099 · DOI:10.3390/ijms25031599 · DOI:10.1111/j.1758-8111.2012.00045.x · DOI:10.14740/jmc3806 · DOI:10.12659/ajcr.930840 · DOI:10.1097/gox.0000000000006173 · DOI:10.1515/hmbci-2017-0076 · DOI:10.1016/j.jpra.2026.01.004 · DOI:10.1055/a-2183-7414 · DOI:10.7759/cureus.11854 · DOI:10.1097/gox.0000000000001043 · DOI:10.1186/s12905-022-02022-3 · DOI:10.2458/lymph.4838 · DOI:10.1097/prs.0000000000012217 · DOI:10.1002/oby.22597 · DOI:10.1111/obr.13953